Skip to main content
Equibles
ZLAB logo

ZLAB · Zai Lab Ltd · Metrics

Track ZLAB — free

Use ZLAB with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research ZLAB.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$23.04 -0.54 (-2.29%) At close · Oct 28 Q2 2026 earnings call transcript
Rebalance outlook locked
Customer concentration — top customer 18% of receivables

One customer — 18% of receivables (As of June 30, 2026)

“As of June 30, 2026, our largest customer accounted for approximately 18% of our total accounts receivable collectively.”
View the 10-Q filed Aug 6, 2026
Market Cap
$2.55B
Shares
112.27M
Volume · Oct 28 704.07K Avg daily vol (3M) 1.03M

ZLAB metrics

89 of 122 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$23.04
Market cap
$2.55B

Price action

20 metrics
Price change (1W)
-6.0%
Price change (30D)
-8.2%
Price change (3M)
+26.6%
Price change (6M)
+6.5%
Price change (YTD)
+33.7%
Price change (1Y)
-10.5%
Trailing year
Price change (5Y)
-77.5%
52-week high
$27.00
52-week low
$16.30
Change from 52-week high
-12.7%
Change from 52-week low
+44.7%
Annualized volatility
51.2%
Annualized volatility (3M)
61.7%
Beta
1.0
RSI (14D)
46.4
Price vs SMA 50
-6.3%
Price vs SMA 200
+12.7%
Avg volume (3M)
1.03M
Relative volume
1.5
Average dollar volume
$25.48M

Company

3 metrics
Sector
Healthcare
Industry
Biotechnology
Shares outstanding
112.27M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
5.0×
reciprocal yield 19.8%
EV / EBITDA
—
EV / EBIT
—
P / sales
5.9×
reciprocal yield 17.0%
P / book
4.4
reciprocal yield 22.9%
FCF yield
-5.3%
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-7.1%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
103.4×
reciprocal yield 1.0%
EV / revenue historical average (5Y)
103.4×
reciprocal yield 1.0%
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
2026-11-05
Last earnings
2026-08-06

Profitability

9 metrics
Gross margin
56.5%
Operating margin
-58.7%
Trailing 12 months
Net margin
-41.9%
Gross profit (TTM)
$254.07M
Operating profit (TTM)
−$264.10M
Net income (TTM)
−$188.21M
Trailing 12 months
Diluted EPS (TTM)
$-1.80
FCF margin
-31.0%
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
$4.06
Gross profit per diluted share (TTM)
$2.29
Operating profit per diluted share (TTM)
$-2.38
EBITDA per diluted share (TTM)
$-2.24
Net income per diluted share (TTM)
$-1.70
Operating cash flow per diluted share (TTM)
$-1.20
Free cash flow per diluted share (TTM)
$-1.26
Capital expenditures per diluted share (TTM)
$0.06
R&D per diluted share (TTM)
$2.14
Stock compensation per diluted share (TTM)
$0.53
Book value per share
$5.41

Growth

11 metrics
Revenue growth YoY
-3.3%
Year over year
Net income growth YoY
—
Revenue (TTM)
$449.61M
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+2.3%
Year over year · more shares
Revenue CAGR (3Y)
+28.9%
Revenue CAGR (5Y)
+56.5%
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
-31.0%
Return on assets
-17.5%
Debt / equity
0.4
Current ratio
2.1
EBITDA (TTM)
−$248.17M
Free cash flow (TTM)
−$139.57M
Quick ratio
1.9
Interest coverage
-44.1
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
$379.42M
Latest balance sheet
Cash & equivalents
$607.52M
Total assets
$1.07B
Total debt
$238.10M

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$133.38M
Capital expenditures (TTM)
$6.19M
R&D (TTM)
$236.92M
SG&A (TTM)
$281.09M
Stock compensation (TTM)
$58.29M
R&D / revenue
52.7%
Stock compensation / revenue
13.0%

Ownership (13F)

9 metrics
13F filers
92
13F filer change QoQ
-7
Institutional ownership
38.7%
Conviction holders (share of 13F filers)
3.3%
Crowding (high-turnover and private-fund holders)
—
Private-fund adviser ownership
—
Active holders' share change QoQ
+48.0%
Holder tenure
9.1
Price vs estimated holder cost
-14.6%

Ownership (registered funds)

1 metrics
Index-fund ownership
0.8%

Short interest

3 metrics
Short interest
7.9%
Latest settlement · 11.3 days to cover
Days to cover
11.3d
Short-squeeze score
78 / 100

Insider activity

2 metrics
Net insider buying (90D)
−$235,145
Insider-sentiment score
—

Risk flags

1 metrics
Going concern
—
Key facts CIK 1704292 CUSIP 98887Q104 13F (30d) 8 filings 8 filers Visit website Investor relations